Emalex is in a late-stage clinical study of a new class of drug for patients with Tourette syndrome who have limited treatment options.
Latest News
Emalex Biosciences Announces $250 Million Financing Round to Advance Investigational New Drug for Tourette Syndrome
Emalex Biosciences to Present Positive Results for Pediatric Tourette Syndrome Study at AAN Annual Meeting
Emalex Biosciences Expands CNS Platform to Advance Treatment for Restless Legs Syndrome with Augmentation
Currently, we are investigating therapies for Tourette syndrome in pediatric patients and childhood-onset fluency disorder—also known as stuttering—in adults. To date, there is only one U.S. Food and Drug Administration (FDA)-approved treatment for Tourette’s and no FDA-approved treatment for childhood-onset fluency disorder.
Latest News
Emalex Biosciences Announces $250 Million Financing Round to Advance Investigational New Drug for Tourette Syndrome
By emalexadmin |
Currently, we are investigating therapies for Tourette syndrome in pediatric patients and childhood-onset fluency disorder—also known as stuttering—in adults. To date, there is only one U.S. Food and Drug Administration (FDA)-approved treatment for Tourette’s and no FDA-approved treatment for childhood-onset fluency disorder.